Chemotherapy

Experimental Chemotherapy

Inhibitory Effect of Azone® (1-Dodecylazacycloheptan-2-one) on Herpes simplex Viruses

In vivo and in vitro Studies

Leonard M.F.a · Kumar A.a · Murray D.L.a · Beaman D.C.b

Author affiliations

aDepartment of Pediatrics and Human Development, and bClinical Center, Michigan State University, East Lansing, Mich., USA

Related Articles for ""

Chemotherapy 1987;33:151–156

Log in to MyKarger to check if you already have access to this content.


Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select
* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Experimental Chemotherapy

Published online: September 09, 2009
Issue release date: 1987

Number of Print Pages: 6
Number of Figures: 0
Number of Tables: 0

ISSN: 0009-3157 (Print)
eISSN: 1421-9794 (Online)

For additional information: https://www.karger.com/CHE

Abstract

Enhanced activity of antiviral agents, when mixed with a penetration enhancer like Azone® (1-dodecylazacycloheptan-2-one) in topical preparations, is well-recognized. These studies were undertaken to investigate whether Azone, per se, has any activity against herpes simplex (HSV) type 1 and type 2 viruses. When HSV-1 and HSV-2 were mixed with 5, 10 and 20% Azone, there was a 1–4.5 log10 decrease in virus titers. The efficacy of 5 and 10% Azone applied topically was evaluated during the treatment of HSV-1 cutaneous infections in guinea pigs. HSV-1 infection was produced by intradermally inoculating guinea pigs with 1077 HSV-1/ml. The mean number of lesions per site was reduced by more than 50% in Azone-treated sites as compared to no treatment (control) sites (p < 0.01). Similarly, the surface area of each lesion in the Azone-treated sites was only 40% of that seen in control sites (p < 0.001). More than 80% of the lesions on Azone-treated sites healed by day 4 as compared to only 3% on control sites (p < 0.001). These data indicate that Azone, a lipophilic chemical, may have antiviral properties when used topically.

© 1987 S. Karger AG, Basel




Related Articles:


Article / Publication Details

First-Page Preview
Abstract of Experimental Chemotherapy

Published online: September 09, 2009
Issue release date: 1987

Number of Print Pages: 6
Number of Figures: 0
Number of Tables: 0

ISSN: 0009-3157 (Print)
eISSN: 1421-9794 (Online)

For additional information: https://www.karger.com/CHE


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
TOP